Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 5/2012

01-05-2012 | Original paper

Family history of malignant and benign thyroid diseases and risk of thyroid cancer: a population-based case–control study in New Caledonia

Authors: Christophe Leux, Thérèse Truong, Claire Petit, Dominique Baron-Dubourdieu, Pascal Guénel

Published in: Cancer Causes & Control | Issue 5/2012

Login to get access

Abstract

Purpose

Exceptionally high incidence rates of thyroid cancer have been observed in New Caledonia, particularly in Melanesian women, but familial aggregation of thyroid diseases in this population is unknown. We study the association between family history of malignant or benign thyroid diseases and non-medullary thyroid cancer in this country.

Methods

We conducted a population-based case–control study including 332 cases with papillary or follicular carcinoma diagnosed in 1993–1999 and 412 controls, matched by sex and 5-year age-group.

Results

Thyroid cancer was associated with a history of thyroid cancer in first-degree relatives (odds ratio (OR), 3.2; 95 % CI, 1.6–6.2) and with a family history of multinodular goiter (OR, 3.6; 95 % CI, 1.9–7.0). The ORs did not change by age at diagnosis and with the number of affected relatives. The study provides evidence that the familial component of thyroid cancer is particularly strong in men. Thyroid cancer was not associated with a family history of thyroid diseases in Melanesians from the Loyalty Islands, the area with the highest incidence rates for thyroid cancer, possibly indicating a high frequency of genetic susceptibility variants and lack of genetic variation in this population subgroup.

Conclusion

Overall our findings confirm an elevated risk of thyroid cancer in individuals with a family history of malignant or benign thyroid diseases, particularly in Melanesians where familial aggregation of thyroid cancer had never been investigated before. The study of genetic variants in candidate susceptibility genes for thyroid cancer may help clarifying the absence of an association in the subgroup of Melanesians from the Loyalty Islands.
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917PubMedCrossRef
2.
Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–781PubMedCrossRef
3.
Cancer incidence in five continents, vol VIII. IARC Science Publication no. 155, pp 1–781 (2002)
4.
Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA (2007) Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ 177(11):1357–1361PubMedCrossRef
5.
Liu S, Semenciw R, Ugnat AM, Mao Y (2001) Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects. Br J Cancer 85(9):1335–1339PubMedCrossRef
6.
Zheng T, Holford TR, Chen Y, Ma JZ, Flannery J, Liu W et al (1996) Time trend and age-period-cohort effect on incidence of thyroid cancer in Connecticut, 1935–1992. Int J Cancer 67(4):504–509PubMedCrossRef
7.
Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295(18):2164–2167PubMedCrossRef
8.
Smailyte G, Miseikyte-Kaubriene E, Kurtinaitis J (2006) Increasing thyroid cancer incidence in Lithuania in 1978–2003. BMC Cancer 6:284PubMedCrossRef
9.
Reynolds RM, Weir J, Stockton DL, Brewster DH, Sandeep TC, Strachan MW (2005) Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol (Oxf) 62(2):156–162CrossRef
10.
Colonna M, Guizard AV, Schvartz C, Velten M, Raverdy N, Molinie F et al (2007) A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983–2000). Eur J Cancer 43(5):891–900PubMedCrossRef
11.
Burgess JR, Tucker P (2006) Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid 16(1):47–53PubMedCrossRef
12.
Leenhardt L, Grosclaude P, Cherie-Challine L (2004) Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 14(12):1056–1060PubMedCrossRef
13.
Yu GP, Li JC, Branovan D, McCormick S, Schantz SP (2010) Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups. Thyroid 20(5):465–473PubMedCrossRef
14.
Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE et al (2009) Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev 18(3):784–791PubMedCrossRef
15.
Truong T, Rougier Y, Dubourdieu D, Guihenneuc-Jouyaux C, Orsi L, Hemon D et al (2007) Time trends and geographic variations for thyroid cancer in New Caledonia, a very high incidence area (1985–1999). Eur J Cancer Prev 16(1):62–70PubMedCrossRef
16.
Truong T, Orsi L, Dubourdieu D, Rougier Y, Hemon D, Guenel P (2005) Role of goiter and of menstrual and reproductive factors in thyroid cancer: a population-based case-control study in New Caledonia (South Pacific), a very high incidence area. Am J Epidemiol 161(11):1056–1065PubMedCrossRef
17.
Guignard R, Truong T, Rougier Y, Baron-Dubourdieu D, Guenel P (2007) Alcohol drinking, tobacco smoking, and anthropometric characteristics as risk factors for thyroid cancer: a countrywide case-control study in New Caledonia. Am J Epidemiol 166(10):1140–1149PubMedCrossRef
18.
Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH (1994) Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86(21):1600–1608PubMedCrossRef
19.
Hemminki K, Vaittinen P (1999) Familial cancers in a nationwide family cancer database: age distribution and prevalence. Eur J Cancer 35(7):1109–1117PubMedCrossRef
20.
Hemminki K, Eng C, Chen B (2005) Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab 90(10):5747–5753PubMedCrossRef
21.
Kerber RA, O’Brien E (2005) A cohort study of cancer risk in relation to family histories of cancer in the Utah population database. Cancer 103(9):1906–1915PubMedCrossRef
22.
Frich L, Glattre E, Akslen LA (2001) Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway. Cancer Epidemiol Biomarkers Prev 10(2):113–117PubMed
23.
Hrafnkelsson J, Tulinius H, Jonasson JG, Sigvaldason H (2001) Familial non-medullary thyroid cancer in Iceland. J Med Genet 38(3):189–191PubMedCrossRef
24.
Galanti MR, Ekbom A, Grimelius L, Yuen J (1997) Parental cancer and risk of papillary and follicular thyroid carcinoma. Br J Cancer 75(3):451–456PubMedCrossRef
25.
Horn-Ross PL, Morris JS, Lee M, West DW, Whittemore AS, McDougall IR et al (2001) Iodine and thyroid cancer risk among women in a multiethnic population: the Bay Area Thyroid Cancer Study. Cancer Epidemiol Biomarkers Prev 10(9):979–985PubMed
26.
Ron E, Kleinerman RA, LiVolsi VA, Fraumeni JF Jr (1991) Familial nonmedullary thyroid cancer. Oncology 48(4):309–311PubMedCrossRef
27.
Mack WJ, Preston-Martin S, Bernstein L, Qian D (2002) Lifestyle and other risk factors for thyroid cancer in Los Angeles County females. Ann Epidemiol 12(6):395–401PubMedCrossRef
28.
Memon A, Berrington De Gonzalez A, Luqmani Y, Suresh A (2004) Family history of benign thyroid disease and cancer and risk of thyroid cancer. Eur J Cancer 40(5):754–760
29.
Brindel P, Doyon F, Bourgain C, Rachedi F, Boissin JL, Sebbag J et al (2010) Family history of thyroid cancer and the risk of differentiated thyroid cancer in French polynesia. Thyroid 20:393–400PubMedCrossRef
30.
Xu L, Li G, Wei Q, El-Naggar AK, Sturgis EM (2011) Family history of cancer and risk of sporadic differentiated thyroid carcinoma. Cancer 118(5):1228–1235
31.
Adjadj E, Schlumberger M, de Vathaire F (2009) Germ-line DNA polymorphisms and susceptibility to differentiated thyroid cancer. Lancet Oncol 10(2):181–190PubMedCrossRef
32.
Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Sigurdsson A, Bergthorsson JT et al (2009) Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet 41(4):460–464PubMedCrossRef
33.
R Development Core Team (2011) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN:3-900051-07-0. http://​www.​R-project.​org
34.
Friedlaender JS, Friedlaender FR, Reed FA, Kidd KK, Kidd JR, Chambers GK et al (2008) The genetic structure of Pacific Islanders. PLoS Genet 4(1):e19PubMedCrossRef
35.
Pal T, Vogl FD, Chappuis PO, Tsang R, Brierley J, Renard H et al (2001) Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab 86(11):5307–5312PubMedCrossRef
36.
Leprat F, Bonichon F, Guyot M, Trouette H, Trojani M, Vergnot V et al (1999) Familial non-medullary thyroid carcinoma: pathology review in 27 affected cases from 13 French families. Clin Endocrinol (Oxf) 50(5):589–594CrossRef
37.
Loh KC (1997) Familial nonmedullary thyroid carcinoma: a meta-review of case series. Thyroid 7(1):107–113PubMedCrossRef
38.
Grossman RF, Tu SH, Duh QY, Siperstein AE, Novosolov F, Clark OH (1995) Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment. Arch Surg 130(8):892–897; discussion 8–9
39.
Lupoli G, Vitale G, Caraglia M, Fittipaldi MR, Abbruzzese A, Tagliaferri P et al (1999) Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet 353(9153):637–639PubMedCrossRef
40.
Alsanea O, Wada N, Ain K, Wong M, Taylor K, Ituarte PH, et al. (2000) Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery 128(6):1043–1050; discussion 50–51
41.
Uchino S, Noguchi S, Kawamoto H, Yamashita H, Watanabe S, Yamashita H et al (2002) Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg 26(8):897–902PubMedCrossRef
42.
Sippel RS, Caron NR, Clark OH (2007) An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up. World J Surg 31(5):924–933PubMedCrossRef
43.
Triponez F, Wong M, Sturgeon C, Caron N, Ginzinger DG, Segal MR et al (2006) Does familial non-medullary thyroid cancer adversely affect survival? World J Surg 30(5):787–793PubMedCrossRef
44.
Maxwell EL, Hall FT, Freeman JL (2004) Familial non-medullary thyroid cancer: a matched-case control study. Laryngoscope 114(12):2182–2186PubMedCrossRef
45.
Mack WJ, Preston-Martin S, Bernstein L, Qian D, Xiang M (1999) Reproductive and hormonal risk factors for thyroid cancer in Los Angeles County females. Cancer Epidemiol Biomarkers Prev 8(11):991–997PubMed
46.
Horn-Ross PL, Canchola AJ, Ma H, Reynolds P, Bernstein L (2011) Hormonal factors and the risk of papillary thyroid cancer in the california teachers study cohort. Cancer Epidemiol Biomarkers Prev 20(8):1751–1759PubMedCrossRef
47.
Fagin JA (1997) Familial nonmedullary thyroid carcinoma—the case for genetic susceptibility. J Clin Endocrinol Metab 82(2):342–344PubMedCrossRef
48.
Burgess JR, Duffield A, Wilkinson SJ, Ware R, Greenaway TM, Percival J et al (1997) Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid. J Clin Endocrinol Metab 82(2):345–348PubMedCrossRef
49.
Bignell GR, Canzian F, Shayeghi M, Stark M, Shugart YY, Biggs P et al (1997) Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet 61(5):1123–1130PubMedCrossRef
50.
Canzian F, Amati P, Harach HR, Kraimps JL, Lesueur F, Barbier J et al (1998) A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 63(6):1743–1748PubMedCrossRef
51.
Malchoff CD, Sarfarazi M, Tendler B, Forouhar F, Whalen G, Joshi V et al (2000) Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab 85(5):1758–1764PubMedCrossRef
52.
McKay JD, Lesueur F, Jonard L, Pastore A, Williamson J, Hoffman L et al (2001) Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 69(2):440–446PubMedCrossRef
53.
He H, Nagy R, Liyanarachchi S, Jiao H, Li W, Suster S et al (2009) A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. Cancer Res 69(2):625–631PubMedCrossRef
54.
Lesueur F, Stark M, Tocco T, Ayadi H, Delisle MJ, Goldgar DE et al (1999) Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium. J Clin Endocrinol Metab 84(6):2157–2162PubMedCrossRef
55.
Bevan S, Pal T, Greenberg CR, Green H, Wixey J, Bignell G et al (2001) A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: confirmation of linkage to TCO1. J Clin Endocrinol Metab 86(8):3701–3704PubMedCrossRef
56.
Cavaco BM, Batista PF, Martins C, Banito A, do Rosario F, Limbert E, et al. (2008) Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. Endocr Relat Cancer 15(1):207–215
57.
Truong T, Baron-Dubourdieu D, Rougier Y, Guenel P (2010) Role of dietary iodine and cruciferous vegetables in thyroid cancer: a countrywide case-control study in New Caledonia. Cancer Causes Control 21(8):1183–1192
58.
59.
Wingren G, Hatschek T, Axelson O (1993) Determinants of papillary cancer of the thyroid. Am J Epidemiol 138(7):482–491PubMed
60.
Paoff K, Preston-Martin S, Mack WJ, Monroe K (1995) A case-control study of maternal risk factors for thyroid cancer in young women (California, United States). Cancer Causes Control 6(5):389–397PubMedCrossRef
61.
Kolonel LN, Hankin JH, Wilkens LR, Fukunaga FH, Hinds MW (1990) An epidemiologic study of thyroid cancer in Hawaii. Cancer Causes Control 1(3):223–234PubMedCrossRef
62.
Preston-Martin S, Jin F, Duda MJ, Mack WJ (1993) A case-control study of thyroid cancer in women under age 55 in Shanghai (People’s Republic of China). Cancer Causes Control 4(5):431–440PubMedCrossRef
63.
D’Avanzo B, La Vecchia C, Franceschi S, Negri E, Talamini R (1995) History of thyroid diseases and subsequent thyroid cancer risk. Cancer Epidemiol Biomarkers Prev 4(3):193–199PubMed
64.
Hallquist A, Hardell L, Degerman A, Boquist L (1994) Thyroid cancer: reproductive factors, previous diseases, drug intake, family history and diet. A case-control study. Eur J Cancer Prev 3(6):481–488PubMedCrossRef
65.
Sokic SI, Adanja BJ, Vlajinac HD, Jankovic RR, Marinkovic JP, Zivaljevic VR (1994) Risk factors for thyroid cancer. Neoplasma 41(6):371–374PubMed
66.
Iribarren C, Haselkorn T, Tekawa IS, Friedman GD (2001) Cohort study of thyroid cancer in a San Francisco Bay area population. Int J Cancer 93(5):745–750PubMedCrossRef
67.
Levi F, Franceschi S, La Vecchia C, Negri E, Gulie C, Duruz G et al (1991) Previous thyroid disease and risk of thyroid cancer in Switzerland. Eur J Cancer 27(1):85–88PubMedCrossRef
68.
Franceschi S, Preston-Martin S, Dal Maso L, Negri E, La Vecchia C, Mack WJ, et al. (1999) A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid diseases. Cancer Causes Control 10(6):583–595
69.
Kerber RA, Slattery ML (1997) Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J Epidemiol 146(3):244–248PubMedCrossRef
70.
Soegaard M, Jensen A, Frederiksen K, Hogdall E, Hogdall C, Blaakaer J et al (2008) Accuracy of self-reported family history of cancer in a large case-control study of ovarian cancer. Cancer Causes Control 19(5):469–479PubMedCrossRef
71.
Mitchell RJ, Brewster D, Campbell H, Porteous ME, Wyllie AH, Bird CC et al (2004) Accuracy of reporting of family history of colorectal cancer. Gut 53(2):291–295PubMedCrossRef
Metadata
Title
Family history of malignant and benign thyroid diseases and risk of thyroid cancer: a population-based case–control study in New Caledonia
Authors
Christophe Leux
Thérèse Truong
Claire Petit
Dominique Baron-Dubourdieu
Pascal Guénel
Publication date
01-05-2012
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 5/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-9944-7

Other articles of this Issue 5/2012

Cancer Causes & Control 5/2012 Go to the issue

Brief report

Mammographic breast density and breast cancer risk by menopausal status, postmenopausal hormone use and a family history of breast cancer

Original paper

Obesity and the incidence of skin cancer in US Caucasians

Original paper

Associations of intakes of fat, dietary fiber, soy isoflavones, and alcohol with levels of sex hormones and prolactin in premenopausal Japanese women

Original paper

Going against the tide: increasing incidence of colorectal cancer among Koreans, Filipinos, and South Asians in California, 1988–2007

Original paper

Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden

Brief report

Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits